AstraZeneca and Bristol-Myers Squibb announce EU approval for diabetes drug Xigduo

The European Commission has granted marketing authorisation to AstraZeneca and Bristol-Myers Squibb's (BMS's) Xigduo (dapagliflozin and metformin hydrochloride in 5mg/850mg and 5mg/1000mg tablets) for the treatment of type 2 diabetes in the European …
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news